Living with haemophilia and von Willebrand's: a descriptive qualitative study.

Patient Educ Couns

Self-Management Programme, Applied Research Centre in Health & Lifestyle Interventions, Faculty of Health & Life Sciences, Coventry University, Priory Street, Coventry CV1 5FB, UK.

Published: November 2007

Objective: The aim of this qualitative descriptive study was to describe the experience of living with bleeding disorders and to identify the associated salient issues from the perspectives of people living with haemophilia or von Willebrand's Disease (vWD).

Methods: Nine members of The Haemophilia Society took part in a semi-structured interview. The interviews were tape recorded and transcribed and the results subjected to thematic content analysis.

Results: Participants described the physical aspects of their condition, such as bleeding into joints, the implications of bleeds and development of co-morbid conditions (e.g. arthritis). Many felt that their bleeding disorder had impacted on their education, work, social activities and family life. Anxiety and depression were associated with daily management of symptoms, the unpredictable nature of bleeding disorders and concerns about the future. All participants had encountered a degree of stigmatisation related to their condition and felt that there was a public misconception about bleeding disorders. Many had experienced discrimination in educational and work settings. Some participants expressed a preference for seeking treatment from specialist services.

Conclusion: Living with haemophilia and vWD poses a number of daily and longer-term challenges not only for individuals, but also for their families. Further investigation of ways to support such individuals is warranted.

Practice Implications: Greater awareness and understanding of the issues faced by people living with haemophilia and vWD is needed for the general public, employers, and healthcare staff, particularly those working in Accident and Emergency Departments.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pec.2007.06.006DOI Listing

Publication Analysis

Top Keywords

living haemophilia
16
bleeding disorders
12
haemophilia von
8
von willebrand's
8
people living
8
haemophilia vwd
8
living
5
bleeding
5
willebrand's descriptive
4
descriptive qualitative
4

Similar Publications

Introduction: Acquired haemophilia A (AHA) is characterized by the development of autoantibodies against factor VIII, reducing its activity and potentially resulting in bleeding.

Aim: To assess the characteristics of people with AHA undergoing rehabilitation and/or with low activities of daily living (ADL) scores, thereby characterizing unmet needs in the management of AHA and informing treatment optimization.

Methods: ORIHIME II, the largest epidemiological and treatment survey of AHA in Japan, is a descriptive, retrospective, observational study conducted using health claims data from April 2008 to October 2021.

View Article and Find Full Text PDF

Background and objectives Hemophilic arthropathy is a known complication of patients with hemophilia, with the knee as the commonest joint affected. Patients with this condition have severe pain and restricted joint mobility, affecting their activities of daily living. Total knee replacement can increase these patients' quality of life.

View Article and Find Full Text PDF

Mechanism of Genome Editing Tools and Their Application on Genetic Inheritance Disorders.

Glob Med Genet

December 2024

Institute of Green Manufacturing Technology, Korea University, Seoul, Republic of Korea.

In the fields of medicine and bioscience, gene editing is increasingly recognized as a promising therapeutic approach for treating pathogenic variants in humans and other living organisms. With advancements in technology and knowledge, it is now understood that most genetic defects are caused by single-base pair variants. The ability to substitute genes using genome editing tools enables scientists and doctors to cure genetic diseases and disorders.

View Article and Find Full Text PDF
Article Synopsis
  • The Phase 3 XTEND-1 trial demonstrated that efanesoctocog alfa provides better bleed protection than standard factor VIII (FVIII) replacement therapies for patients with severe hemophilia A.
  • A systematic literature review was conducted to compare bleeding outcomes between efanesoctocog alfa and different types of FVIII therapies, using statistical methods to analyze annualized bleeding rates (ABRs).
  • Results showed that efanesoctocog alfa was linked to significantly fewer annual bleeds, averaging 2.2 fewer versus extended half-life therapies and 3.6 fewer versus standard therapies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!